JP2017530954A - トロポニンのエラスターゼから独立した増加と関連する障害のためのエラフィンの使用 - Google Patents

トロポニンのエラスターゼから独立した増加と関連する障害のためのエラフィンの使用 Download PDF

Info

Publication number
JP2017530954A
JP2017530954A JP2017511942A JP2017511942A JP2017530954A JP 2017530954 A JP2017530954 A JP 2017530954A JP 2017511942 A JP2017511942 A JP 2017511942A JP 2017511942 A JP2017511942 A JP 2017511942A JP 2017530954 A JP2017530954 A JP 2017530954A
Authority
JP
Japan
Prior art keywords
troponin
elafin
polypeptide
elastase
surgery
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017511942A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017530954A5 (enExample
Inventor
バーグマン，バージ
ウィドウ，オリバー
ヘンリクセン，ピーター
Original Assignee
プロテオ バイオテック アーゲー
プロテオ バイオテック アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by プロテオ バイオテック アーゲー, プロテオ バイオテック アーゲー filed Critical プロテオ バイオテック アーゲー
Publication of JP2017530954A publication Critical patent/JP2017530954A/ja
Publication of JP2017530954A5 publication Critical patent/JP2017530954A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Medical Uses (AREA)
JP2017511942A 2014-08-26 2015-08-24 トロポニンのエラスターゼから独立した増加と関連する障害のためのエラフィンの使用 Pending JP2017530954A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102014216985 2014-08-26
DE102014216985.2 2014-08-26
PCT/EP2015/069341 WO2016030323A1 (en) 2014-08-26 2015-08-24 Use of elafin for disorders associated with elastase independent increase in troponin

Publications (2)

Publication Number Publication Date
JP2017530954A true JP2017530954A (ja) 2017-10-19
JP2017530954A5 JP2017530954A5 (enExample) 2019-01-24

Family

ID=54011022

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017511942A Pending JP2017530954A (ja) 2014-08-26 2015-08-24 トロポニンのエラスターゼから独立した増加と関連する障害のためのエラフィンの使用

Country Status (4)

Country Link
US (5) US20180221462A1 (enExample)
EP (1) EP3185892B1 (enExample)
JP (1) JP2017530954A (enExample)
WO (1) WO2016030323A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190060506A1 (en) * 2017-08-22 2019-02-28 The Board Of Trustees Of The Leland Stanford Junior University Elafin Incorporated Biomaterials for the Treatment of Chronic Tissue Ulcers
WO2021195672A1 (en) * 2020-03-26 2021-09-30 The Regents Of The University Of California Detection and treatment of intestinal fibrosis

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011107505A1 (en) * 2010-03-03 2011-09-09 Proteo Biotech Ag Novel uses of elafin

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999043308A2 (en) * 1998-02-27 1999-09-02 Marlene Rabinovitch Treating pulmonary hypertension through tenascin suppression and elastase inhibition
CN1838964A (zh) * 2002-04-25 2006-09-27 斯克里普斯研究学院 肺病的治疗与预防

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011107505A1 (en) * 2010-03-03 2011-09-09 Proteo Biotech Ag Novel uses of elafin

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
EUROPEAN JOURNAL OF PHYSIOLOGY, vol. 433, JPN6019022548, 1997, pages 563 - 570, ISSN: 0004250340 *
メルクマニュアル, vol. 第１８版, JPN6019022549, 2006, pages 667 - 674, ISSN: 0004250341 *

Also Published As

Publication number Publication date
EP3185892B1 (en) 2020-02-12
US20220111021A1 (en) 2022-04-14
US20230285524A1 (en) 2023-09-14
EP3185892A1 (en) 2017-07-05
US20190255158A1 (en) 2019-08-22
US20220133867A1 (en) 2022-05-05
WO2016030323A1 (en) 2016-03-03
US20180221462A1 (en) 2018-08-09

Similar Documents

Publication Publication Date Title
Weigert et al. Angiotensin II induces human TGF-β1 promoter activation: similarity to hyperglycaemia
Sato et al. Pro-carboxypeptidase R is an acute phase protein in the mouse, whereas carboxypeptidase N is not
Wang et al. Antithrombin is protective against myocardial ischemia and reperfusion injury
Lin et al. Endostatin and transglutaminase 2 are involved in fibrosis of the aging kidney
JP5857035B2 (ja) 止血活性を持つ組織因子を有するリン脂質に富んだ小胞及びその使用
JP2002532068A (ja) 血管新生阻害タンパク質に結合するタンパク質およびそれを使用した組成物および方法
US20230285524A1 (en) Use of elafin for disorders associated with elastase independent increase in troponin
WO2014152089A1 (en) Compositions and treatments of metabolic disorders using fgf binding protein 3
US20140287985A1 (en) Novel uses of elafin
CA2802072A1 (en) Treatment of coagulopathy with hyperfibrinolysis
US20080118933A1 (en) Methods of screening for inhibitors of antiplasmin cleaving enzyme
WO2008124172A1 (en) Combination therapy for chronic dermal ulcers
Xu et al. Factor VII deficiency impairs cutaneous wound healing in mice
CZ200240A3 (cs) Léčivo s obsahem agonisty nebo antagonisty tkáňového faktoru pro regulaci buněčné migrace
Du et al. Characterization and structural analysis of a potent anticoagulant phospholipase A2 from Pseudechis australis snake venom
CA2709337A1 (en) Haemostasis- modulating compositions and uses therefor
JP2007513881A (ja) Ｘｉ因子の治療学的使用
DK175408B1 (da) Isohirudiner, fremgangsmåde til deres fremstilling, pharmaceutisk middel samt fremgangsmåde til dets fremstilling
JP7025928B2 (ja) 外科的介入後の腹膜の癒着を予防または治療するための医薬組成物および医薬組成物の使用
US20090170760A1 (en) Anti-Cancer Agent Comprising Protein C Inhibitor
EP1531845A2 (en) Inhibitors for use in hemostasis
JP2015147744A (ja) Ｐａｉ−１阻害剤
Nock Development of an enzyme immunoassay and cellular function assays to probe the function of teneurin C-terminal associated peptide (TCAP)
KR20080016675A (ko) 세포 핵-엔터링 조성물
US20060269537A1 (en) Glycosyl phosphatidyl inositol specific phospholipase D proteins and uses thereof

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A525

Effective date: 20170421

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20171109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20171109

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180727

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181207

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190618

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190912

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191118

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200407